Combivir is an oral drug that is a combination of lamivudine Epivir and zidovudine Retrovir. It is used for the treatment of infections with the human immunodeficiency virus HIV. Lamivudine and zidovudine are in a class of drugs called reverse transcriptase inhibitors that also includes zalcitabine Hivid and didanosine Videx.

During infection with HIV the HIV virus multiplies within the bodys cells. The newly-formed viruses are released from the cells and then spread throughout the body where they infect other cells. In this manner the infection continually spreads to new uninfected cells that the body is continually producing and HIV infection is perpetuated. When producing new viruses the HIV virus must manufacture new DNA for each virus. Reverse transcriptase is the enzyme that the virus uses to form this new DNA. Lamivudine and zidovudine block the activity of reverse transcriptase and block the production of DNA and new viruses. Specifically lamivudine is converted within the body to its active form lamivudine triphosphate and zidovudine is converted to its active form zidovudine triphosphate. The active forms are similar to the naturally occurring deoxycytidine triphosphate and thymidine triphosphate respectively chemicals that are used by reverse transcriptase to make DNA. The reverse transcriptase uses lamivudine triphosphate and zidovudine triphosphate instead of the naturally-occurring deoxycytidine triphosphate and thymidine triphosphate for making DNA and these active forms of the drugs interfere with the activity of reverse transcriptase.

The effectiveness of either lamivudine or zidovudine when used alone may decrease as the HIV virus develops resistance to the effects of the individual drugs. By combining lamivudine and zidovudine it is more difficult for the HIV virus to develop resistance to therapy since it must develop resistance to both drugs. As a result Combivir is more effective than lamivudine or zidovudine alone. Combivir does not kill existing HIV virus and it is not a cure for HIV. Combivir was approved by the FDA in September 1997.

For the treatment of HIV infection the recommended oral dose for adults or children greater than 12 years of age is one tablet twice daily. Combivir is administered without regard to meals since food does not affect its absorption.

The most serious side effects of Combivir are a decrease in blood cells muscle pain myopathy or muscle breakdown rhabdomyolysis liver enlargement and metabolic disturbance lactic acidosis. Other side effects include chills rash abdominal pain nausea and vomiting weight loss headache cough and insomnia. Accumulation or redistribution of fat may also occur.

Fluconazole Diflucan probenecid trimethoprim Trimpex and valproic acid Depakote reduce the elimination of zidovudine and therefore increase the blood concentration of zidovudine. This can lead to increased side effects from zidovudine.

PREGNANCY: Use of Combivir during pregnancy has not been adequately evaluated.

If the victim has collapsed or is not breathing call local emergency services at 911.

In case of overdose call your local poison control center at 1-800-222-1222.

Combivir is used in combination with other agents for the treatment of HIV infection.

Store at 2-30°C 36-86°F.